title: Acute infusion reactions induced by monoclonal antibody therapy.
abstract: This article reports recent evidence on epidemiological data concerning monoclonal antibody (mAb) infusion-related anaphylaxis, as well as recent data on the correlation between mAb immunogenicity and safety profiles. Pathogenic mechanisms of mAb-related adverse reactions including hypersensitivity, IgE- and non-IgE-mediated events and cytokine release syndrome are also highlighted. Finally, the role of serum anti-mAb antibodies as markers to monitor the safety of such therapeutical compounds are extensively evaluated. The anaphylaxis occurring during therapy with the anti-TNF-α mAb infliximab, largely used in immune-mediated diseases, has been taken as a paradigm.
authors.affiliation: Center for Research, Transfer and High Education DENOTHE, University of Florence, Policlinico di Careggi, Viale Morgagni 85, 50134 Florence, Italy. e.maggi@dmi.unifi.it
authors.forename: Enrico
authors.initials: E
authors.lastname: Maggi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Vultaggio
authors.forename: Andrea
authors.initials: A
authors.lastname: Matucci
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced* / Q000453:epidemiology* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D000069285:Infliximab; D007262:Infusions, Intravenous / Q000009:adverse effects*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D007073:Immunoglobulin E; D000069285:Infliximab